Edition:
United States

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

10.69EUR
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
€10.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
21,802
52-wk High
€11.20
52-wk Low
€8.41

Chart for

About

Mithra Pharmaceuticals SA is a Belgium-based company that provides pharmaceutical services. It was founded in 1999.

Overall

Beta: --
Market Cap(Mil.): €364.34
Shares Outstanding(Mil.): 34.24
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Mithra Pharmaceuticals Finalizes Estelle Contract With Libbs

* FINALIZES ESTELLE CONTRACT WITH BRAZILIAN WOMEN’S HEALTH LEADER LIBBS

Dec 11 2017

BRIEF-Mithra Announces Valorization Of French Subsidiary

* SUCCESSFULLY DIVESTED ITS FRENCH AFFILIATE, MITHRA FRANCE‍​

Dec 07 2017

BRIEF-Mithra Pharmaceuticals Announces Update On Clinical Study Progress For Estelle And Donesta‍​

* ANNOUNCES AN UPDATE ON THE CLINICAL STUDY PROGRESS FOR ESTELLE AND DONESTA‍​

Nov 30 2017

BRIEF-Mithra Pharmaceuticals announces 36-month shelf life extension for Tibelia​

* ‍MITHRA ANNOUNCES 36-MONTH SHELF LIFE EXTENSION FOR TIBELIA​

Nov 22 2017

BRIEF-Mithra Pharmaceuticals: ‍positive outcome of Myring commercial batch bioequivalence study​

* ‍POSITIVE OUTCOME OF MYRING COMMERCIAL BATCH BIOEQUIVALENCE STUDY

Nov 17 2017

BRIEF-Mithra Pharmaceuticals ‍completes recruitment for Estelle Phase III study in US and Canada​

* ‍COMPLETES RECRUITMENT FOR ESTELLE® PHASE III STUDY IN US AND CANADA​

Oct 30 2017

BRIEF-Mithra Pharmaceuticals' application for Tibelia marketing authorization accepted by Health Canada‍​

* MITHRA’S MARKETING AUTHORIZATION APPLICATION FOR TIBELIA ACCEPTED BY HEALTH CANADA‍​

Oct 10 2017

BRIEF-Mithra Pharmaceuticals signs commercial agreement with Libbs

* MITHRA PHARMACEUTICALS SA - MITHRA SIGNS COMMERCIAL AGREEMENT WITH BRAZILIAN LEADER IN WOMEN’S HEALTH LIBBS FOR ESTELLE® IN BRAZIL

Sep 26 2017

BRIEF-Mithra Pharmaceuticals H1 operating loss widens to 23.2 million euros

* H1 OPERATING LOSS EUR 23.2 MILLION VERSUS LOSS OF EUR 21.0 MILLION YEAR AGO

Sep 21 2017

BRIEF-Mithra Pharmaceuticals announces first subject completes Estelle phase III study

* ESTELLE PHASE III STUDIES REMAIN ON TRACK TO REPORT TOP LINE RESULTS IN Q3 2018 AND Q1 2019 IN EUROPE/RUSSIA AND THE US/CANADA RESPECTIVELY Further company coverage: (Gdynia Newsroom)

Aug 18 2017

Earnings vs. Estimates